WOBURN, Mass., June 03, 2026 (GLOBE NEWSWIRE) -- Curiox Biosystems today launched two new software capabilities for its Pluto Workstation that automate flow cytometry sample preparation from antibody ...
Curiox Biosystems Signs Master Software License Agreement for Enterprise-Scale Pluto Code Deployment
WOBURN, Mass., April 21, 2026 (GLOBE NEWSWIRE) -- Curiox Biosystems today announced the signing of a Master Software License Agreement with a major global pharmaceutical organization for the ...
The Curiox C- Free Pluto ALPHA replaces traditional centrifuge-based methods, offering a low-maintenance solution that eliminates bulky hardware. Utilizing a pipette head, it delivers gentle, ...
The share price of Curiox Biosystems has surged significantly this year. Despite expectations of a large operating loss again this year, the company's corporate value is rising on the back of strong ...
SEOUL, SOUTH KOREA, Aug. 14, 2023 /PRNewswire/ -- Curiox Biosystems Inc., a global leader in providing innovative and automated sample preparation solutions for accurate and reproducible cell analysis ...
Curiox Biosystems Co. Ltd. Curiox Biosystems Co., Ltd. engages in the sale of automated equipment and consumables for cell analysis processes. Its products include cell pre-processing automation ...
Curiox Biosystems, a global leader in providing innovative and automated sample preparation solutions for accurate and reproducible cell analysis, is pleased to announce its collaboration with Dr.
Curiox Biosystems Signs Master Software License Agreement for Enterprise-Scale Pluto Code Deployment
First master licensing framework for Pluto Code enables a global pharmaceutical organization to expand centrifuge-free automation across its liquid-handling infrastructure without repeated contracting ...
Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. International stock ...
Find the Curiox BioSystems financial statements for a comprehensive overview of the company’s financial health. This summary highlights critical numbers from key financial reports, including the ...
Determining whether Curiox BioSystems Co Ltd—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess the current ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results